In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Foundations of High-Value Discovery Deals

Executive Summary

At a time when high-cash discovery deals, and particularly platform deals, are increasingly difficult to find, a number of companies have pursued alternative strategies for creating important transactions. In the first place, many biotechs have changed their attitude to technology transfer, willingly selling technology, and sacrificing any product-related upside from their clients' programs, in return for more significant upfront funding to pay for creating a more integrated in-house discovery effort. Several companies have also, by focusing efforts on just a few partners, expanded the relationships into a series of deeper and more valuable collaborations. Other biotechs have recognized the value of barter, trading off cash compensation for assets, like combinatorial chemistry expertise, assays, cell lines or even product candidates, which allows them to build internal value faster.
Advertisement

Related Content

Tularik & Amgen: A Model of Business Development (and Good News for Biotech, Too)
Pharmacia Buys into NeoGenesis' Assay-less Screening Approach
Pfizer R&D: The Biggest Pharmaceutical Experiment
Why Pharma Needs to Do Early-Stage Deals
In Context: Aventis-Genta after Bristol-ImClone
Terra Infirma: Pharma Dealmaking 2001
ArQule Takes the Drug Discovery Plunge
ArQule Takes the Drug Discovery Plunge
Playing the High-Stakes Pharma Game, Part I
Playing the High-Stakes Pharma Game, Part I

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel